Skip to main content
Journal cover image

883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer

Publication ,  Conference
Randall, LM; O'Malley, DM; Monk, BJ; Coleman, RL; O'Cearbhaill, RE; Gaillard, S; Adams, S; Cappuccini, F; Huang, M; Chon, HS; Secord, AA ...
Published in: Annals of Oncology
September 2020

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2020

Volume

31

Start / End Page

S646 / S647

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Randall, L. M., O’Malley, D. M., Monk, B. J., Coleman, R. L., O’Cearbhaill, R. E., Gaillard, S., … Konstantinopoulos, P. (2020). 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. In Annals of Oncology (Vol. 31, pp. S646–S647). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.1022
Randall, L. M., D. M. O’Malley, B. J. Monk, R. L. Coleman, R. E. O’Cearbhaill, S. Gaillard, S. Adams, et al. “883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer.” In Annals of Oncology, 31:S646–47. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1022.
Randall LM, O’Malley DM, Monk BJ, Coleman RL, O’Cearbhaill RE, Gaillard S, et al. 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. In: Annals of Oncology. Elsevier BV; 2020. p. S646–7.
Randall, L. M., et al. “883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S646–47. Crossref, doi:10.1016/j.annonc.2020.08.1022.
Randall LM, O’Malley DM, Monk BJ, Coleman RL, O’Cearbhaill RE, Gaillard S, Adams S, Cappuccini F, Huang M, Chon HS, Secord AA, Arora S, Keeton E, Gupta D, Samnotra V, Konstantinopoulos P. 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. Annals of Oncology. Elsevier BV; 2020. p. S646–S647.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2020

Volume

31

Start / End Page

S646 / S647

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis